Women’s perceptions of the adoption of personalised risk-based breast cancer screening and primary prevention: a systematic review

References

• Pharoah PDP, Antoniou AC, Easton DF, et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008;358:2796–2803.
   PubMed Web of Science ®Google Scholar
• Vilaprinyo E, Forne C, Carles M, et al. Cost- effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. Plos One. 2014;9:e86858.
   PubMed Web of Science ®Google Scholar
• Rondy M, van Lier A, van de Kassteele J, et al. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine. 2010;28(9):2070–2075.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Cancer. Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Update of clinical guideline 14 and 41. Clinical guideline 164. 2013. London: NCCC. Available from: http://guidance.nice.org.uk/CG164
   Google Scholar
• Wilmot EG, Edwardson CL, Achana FA, et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia. 2012;55:2895–2905.
   PubMed Web of Science ®Google Scholar
• CASP. Critical appraisal skills programme (CASP): Making sense of evidence. 2011. Available from http://www.casp-uk.net/
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Borenstein M, Hedges LV, Higgins J, Rothstein HR. An introduction to meta-analysis. Hoboken, NJ: John Wiley & Sons, Ltd 2009.
   Google Scholar
• Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.
   Google Scholar
• Gorin SS, Wang C, Raich P, et al. Decision-making in cancer primary prevention and chemoprevention. Ann Behav Med. 2006;32(3):179–187.
   PubMed Web of Science ®Google Scholar
• Henneman L, Timmermans DR, Bouwman CM, et al. ‘A low risk is still a risk’: exploring women’s attitudes towards genetic testing for breast cancer susceptibility in order to target disease prevention. Pub Health Genomics. 2011;14:238–247.
   PubMed Web of Science ®Google Scholar
• Koitsalu M, Sprangers MA, Eklund M, et al. Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer. Acta Oncol. 2016;55:45–51.
   PubMed Web of Science ®Google Scholar
• Phelps C, Wood F, Bennett P, et al. Knowledge and expectations of women undergoing cancer genetic risk assessment: a qualitative analysis of free-text questionnaire comments. J Genet Couns. 2007;16:505–514.
   PubMedGoogle Scholar
• Meisel SF, Pashayan N, Rahman B, et al. Adjusting the frequency of mammography screening on the basis of genetic risk: attitudes among women in the UK. Breast. 2015;24:237–241.
   PubMed Web of Science ®Google Scholar
• Wright CE, Harvie M, Howell A, et al. Beliefs about weight and breast cancer: an interview study with high risk women following a 12 month weight loss intervention. Hered Cancer Clin Pract. 2015;13:1–9.
   Web of Science ®Google Scholar
• Lerman C, Rimer BK, Daly M, et al. Recruiting high risk women into a breast cancer health promotion trial. Cancer Epidemiol Biomarkers Prev. 1994;3:271–276.
   PubMed Web of Science ®Google Scholar
• Heisey R, Pimlott N, Clemons M, et al. Women’s views on chemoprevention of breast cancer: qualitative study. Can Fam Physician. 2006;52:624–625.
   PubMedGoogle Scholar
• Bober SL, Hoke LA, Duda RB, et al. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol. 2004;22:4951–4957.
   PubMed Web of Science ®Google Scholar
• Port ER, Montgomery LL, Heerdt AS, et al. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8:580–585.
   PubMed Web of Science ®Google Scholar
• Fasching PA, von Minckwitz G, Fischer T, et al. The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs. Breast Cancer Res Treat. 2007;101:95–104.
   PubMed Web of Science ®Google Scholar
• Altschuler A, Somkin CP. Women’s decision-making about whether or not to use breast cancer chemoprevention. Women Health. 2005;41:81–95.
   Web of Science ®Google Scholar
• Dillard AJ, Ubel PA, Smith DM, et al. The distinct role of comparative risk perceptions in a breast cancer prevention program. Ann Behav Med. 2001;42:262–268.
   Web of Science ®Google Scholar
• Meiser B, Butow P, Price M, et al. Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. J Womens Health. 2003;12:769–778.
   Web of Science ®Google Scholar
• Hallowell, N. ‘You don’t want to lose your ovaries because you think “I might become a man”’. Women’s perceptions of prophylactic surgery as a cancer risk management option. Psycho-oncol. 1998;7:263–275.
   PubMed Web of Science ®Google Scholar
• Roetzheim RG, Lee JH, Fulp W, et al. Acceptance and adherence to chemoprevention among women at increased risk of breast cancer. Breast. 2015;24:51–56.
   PubMed Web of Science ®Google Scholar
• Meiser B, Butow P, Friedlander M, et al. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol. 2000;18:2250–2257.
   PubMed Web of Science ®Google Scholar
• Salant T, Ganschow PS, Olopade OI, et al. ‘Why take it if you don’t have anything?’ Breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med. 2006;21:779–785.
   PubMed Web of Science ®Google Scholar
• McKay A, Martin W, Latosinsky S. How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide. Breast Cancer Res Treat. 2005;94:153–159.
   PubMed Web of Science ®Google Scholar
• Karp J, Brown KL, Sullivan MD, et al. The prophylactic mastectomy dilemma: a support group for women at high genetic risk for breast cancer. J Genet Couns. 1999;8:163–173.
   PubMedGoogle Scholar
• Hatcher MB, Fallowfield LJ. A qualitative study looking at the psychosocial implications of bilateral prophylactic mastectomy. Breast. 2003;12:1–9.
   PubMed Web of Science ®Google Scholar
• Donnelly LS, Evans DG, Wiseman J, et al. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer. 2014;110:1681–1687.
   PubMed Web of Science ®Google Scholar
• Holmberg C, Daly M, McCaskill‐Stevens W. Risk scores and decision-making: the anatomy of a decision to reduce breast cancer risk. J Nurs Healthc Chronic Illn. 2010;2(4):271–280.
   PubMedGoogle Scholar
• Fisher B, Dowding D, Pickett KE, et al. Health promotion at NHS breast cancer screening clinics in the UK. Health Promot Int. 2007;22:137–1145.
   PubMed Web of Science ®Google Scholar
• Fang CY, Tseng M, Daly MB. Correlates of soy food consumption in women at increased risk for breast cancer. J Am Diet Assoc. 2005;105:1552–1558.
   PubMedGoogle Scholar
• Kaplan CP, Kim SE, Wong ST, et al. Willingness to use tamoxifen to prevent breast cancer among diverse women. Breast Cancer Res Treat. 2012;133:357–366.
   PubMed Web of Science ®Google Scholar
• Julian‐Reynier CM, Bouchard LJ, Evans DG, et al. Women’s attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another. Cancer 2001;92:959–968.
   PubMed Web of Science ®Google Scholar
• Anderson, EE, Tejeda S, Childers K, et al. Breast cancer risk assessment among low-income women of color in primary care: a pilot study. J Oncol Pract. 2015;11:e460–e467.
   PubMed Web of Science ®Google Scholar
• Razzaboni E, Toss A, Cortesi L, et al. Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy). Breast J. 2013;19:10–21.
   PubMed Web of Science ®Google Scholar
• Tjia J, Micco E, Armstrong K. Interest in breast cancer chemoprevention among older women. Breast Cancer Res Treat. 2008;108:435–453.
   PubMed Web of Science ®Google Scholar
• Holmberg C, Waters EA, Whitehouse K, et al. My lived experiences are more important than your probabilities: the role of individualized risk estimates for decision-making about participation in the study of tamoxifen and raloxifene (STAR). Med Decis Making. 2015;35:1010–1022.
   PubMed Web of Science ®Google Scholar
• Aktas B, Sorkin M, Pusztai L, et al. Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. Eur J Cancer Prev. 2016;25:3–8.
   PubMed Web of Science ®Google Scholar
• Cyrus‐David MS, Strom SS. Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer. Psycho-oncology 2001;10(6):521–533.
   PubMed Web of Science ®Google Scholar
• Daly M, Seay J, Balshem A, et al. Feasibility of a telephone survey to recruit health maintenance organization members into a tamoxifen chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 1992;1:413–416.
   PubMed Web of Science ®Google Scholar
• Fagerlin A, Zikmund-Fisher BJ, Smith DM, et al. Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat. 2010;119:613–620.
   PubMed Web of Science ®Google Scholar
• Melnikow J, Paterniti D, Azari R, et al. Preferences of women evaluating risks of tamoxifen(POWER): study of preferences for tamoxifen for breast cancer risk reduction. Cancer 2005;103:1996–2005.
   PubMed Web of Science ®Google Scholar
• Yeomans-Kinney A, Vernon SW, Frankowski RF, et al. Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Cancer. 1995;76:46–56.
   PubMed Web of Science ®Google Scholar
• Khazaee-Pool M, Montazeri A, Majlessi F, et al. Breast cancer preventive behaviors: exploring Iranian women’s experiences. BMC Womens Health. 2014;14:41–50.
   PubMed Web of Science ®Google Scholar
• Dillard AJ, Scherer L, Ubel PA, et al. Breast cancer anxiety’s associations with responses to a chemoprevention decision aid. Soc Sci Med. 2013;77:13–19.
   PubMed Web of Science ®Google Scholar
• Bastian LA, Lipkus IM, Kuchibhatla MN, et al. Women’s interest in chemoprevention for breast cancer. Arch Intern Med. 2001;161:1639–1644.
   PubMed Web of Science ®Google Scholar
• Stefanek M, Enger C, Benkendorf J, et al. Bilateral prophylactic mastectomy decision-making: a vignette study. Prev Med. 1999;29:216–221.
   PubMed Web of Science ®Google Scholar
• Lloyd SM, Watson M, Oaker G, et al. Understanding the experience of prophylactic bilateral mastectomy: a qualitative study of ten women. Psycho-oncol. 2000;9:473–485.
   PubMed Web of Science ®Google Scholar
• Begum P, Richardson CE, Carmichael AR. Obesity in post-menopausal women with a family history of breast cancer: prevalence and risk awareness. Int Semin Surg Oncol. 2009;6:1–5.
   PubMedGoogle Scholar
• Rondanina G, Puntoni M, Severi G, et al. Psychological and clinical factors implicated in decision-making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol. 2008;26:1537–1543.
   PubMed Web of Science ®Google Scholar
• McLeish L, Reis MM, Stewart C, et al. Lifestyle changes in women at genetic risk of breast cancer: an observational study. Int J Behav Med. 2013;20:514–521.
   PubMed Web of Science ®Google Scholar
• Spector D, Mishel M, Skinner CS, et al. Breast cancer risk perception and lifestyle behaviors among white and black women with a family history. Cancer Nurs. 2009;32:299–317.
   PubMed Web of Science ®Google Scholar
• Grann VR, Patel P, Bharthuar A, et al. Breast cancer-related preferences among women with and without BRCA mutations. Breast Cancer Res Treat. 2010;119:177–184.
   PubMed Web of Science ®Google Scholar
• Ozanne EM, Wittenberg E, Garber JE, et al. Breast cancer prevention: patient decision-making and risk communication in the high risk setting. Breast J. 2010;16:38–47.
   Google Scholar
• Unruh HK, Bowen DJ, Meischke H, et al. Women’s approaches to the use of new technology for cancer risk information. Womens Health. 2004;40:59–78.
   Web of Science ®Google Scholar
• Stacey D, DeGrasse C, Johnston L. Addressing the support needs of women at high risk for breast cancer: evidence-based care by advanced practice nurses. Oncol Nurs Forum. 2002;29:77–84.
   Google Scholar
• Bernhardt BA, Geller G, Strauss M, et al. Toward a model informed consent process for BRCA1 testing: a qualitative assessment of women’s attitudes. J Genet Counsel. 1997;6:207–222.
   Google Scholar
• Papies EK. Health goal priming as a situated intervention tool: how to benefit from nonconscious motivational routes to health behaviour. Health Psychol Rev. 2016;10:408–424.
   Google Scholar
• Webb TL, Sheeran P. Does changing behavioral intentions engender behavior change? A meta-analysis of the experimental evidence. Psychol Bull. 2006;132:249–268.
   PubMed Web of Science ®Google Scholar
• Evans DG, Brentnall AR, Harvie M, et al. Breast cancer risk in young women in the National Breast Screening Programme: implications for applying NICE guidelines for additional screening and chemoprevention. Cancer Prev Res. 2014;7(10):993–1001.
   Google Scholar
• Evans DGR, Donnelly LS, Harkness EF, et al. Breast cancer risk feedback to women in the UK NHS breast screening population. Br J Cancer. 2016;114(9):1045–1052.
   PubMed Web of Science ®Google Scholar
• Hollands GJ, Marteau TM, Fletcher PC. Non-conscious processes in changing health-related behaviour: a conceptual analysis and framework. Health Psychol Rev. 2016;10(4):381–394.
   PubMed Web of Science ®Google Scholar
• Harmsen MG, Hermens RP, Prins JB, et al. How medical choices influence quality of life of women carrying a BRCA mutation. Crit Rev Oncol Hematol. 2015;96(3):555–568.
   PubMed Web of Science ®Google Scholar
• Howell A, Anderson AS, Clarke RB, et al. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16(5):446.
   PubMed Web of Science ®Google Scholar
• Harvie M, Cohen H, Mason C, et al. Adherence to a diet and exercise weight loss intervention amongst women at increased risk of breast cancer. Open Obes J. 2010;2:71–80.
   Google Scholar
• Kushi LH, Doyle C, McCullough M, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention. CA Cancer J Clinicians. 2012;62(1):30–67.
   PubMed Web of Science ®Google Scholar
• van Asperen CJ, Tollenaar RA, Krol-Warmerdam EM, et al. Possible consequences of applying guidelines to healthy women with a family history of breast cancer. Eur J Hum Genet. 2003;11:633–667.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381:1827–1834.
   PubMed Web of Science ®Google Scholar
• Loehberg CR, Jud SM, Haeberle L, et al. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. Breast Cancer Res Treat. 2010;121(1):101–110.
   PubMed Web of Science ®Google Scholar
• Decensi A, Robertson C, Viale G, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst. 2003;95(11):779–790.
   PubMedGoogle Scholar
• DeCensi A, Thorat MA, Bonanni B, et al. Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. Ecancermedicalscience 2015;9:595–607.
   PubMed Web of Science ®Google Scholar
• Edwards AG, Naik G, Ahmed H, et al. Personalised risk communication for informed decision-making about taking screening tests. Cochrane Library. 2013.
   Google Scholar
• Trevena LJ, Zikmund-Fisher BJ, Edwards A, et al. Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak. 2013;13:S7.
   PubMed Web of Science ®Google Scholar
• Speice J, McDaniel SH, Rowley PT, et al. Family issues in a psychoeducation group for women with a BRCA mutation. Clin Genet. 2002;62(2):121–127.
   PubMed Web of Science ®Google Scholar
• Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28(18):3090–3095.
   PubMed Web of Science ®Google Scholar
• Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122(9):2017–2022.
   PubMed Web of Science ®Google Scholar
• Miller WR, Rollnick S. Motivational interviewing: preparing people to change addictive behavior. New York: Guilford Press. 1991.
   Google Scholar
• Becker MH. The Health Belief Model and personal health behaviour. Health Education. 1974;2(3):324–508.
   Google Scholar
• Hagger MS, Wood C, Stiff C, et al. The strength model of self-regulation failure and health-related behaviour. Health Psychol Rev. 2009;3(2):208–238.
   Web of Science ®Google Scholar
• Myers RE. Decision counseling in cancer prevention and control. Health Psychol. 2005;24:S71–S77.
   PubMed Web of Science ®Google Scholar